AstraZeneca Collaborates With Ethris

AstraZeneca and its biologics research and development arm MedImmune have entered into a five-year strategic research collaboration with Ethris, a German developer of mRNA-based drugs with a focus on pulmonary disease. The collaboration will target the development of RNA therapies for respiratory diseases using Ethris’ proprietary SNIM RNA technology, Ethris said in a statement.

Under the agreement, AstraZeneca will pay Ethris EUR25 million ($29.4 million) upfront and will provide research funding. Ethris will also be eligible for future research and development milestones, including sales royalties when products are commercialized. Both companies will have the option to take exclusive worldwide licenses when research plans are completed for each target within the collaboration.

Leave a Reply

Your email address will not be published. Required fields are marked *